Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.
Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. Radiother Oncol. 2016 11; 121(2):232-238.